Gynecologic Cancer Models
Ovarian organoids model high-grade serous ovarian cancer and other subtypes. Critical for platinum response prediction and PARP inhibitor selection in BRCA-mutated tumors.
Model the most common and lethal ovarian cancer subtype.
Predict response to PARP inhibitors in BRCA-mutated tumors.
Ovarian cancer is the deadliest gynecological cancer, with most patients diagnosed at advanced stages and developing resistance to chemotherapy. Ovarian cancer organoids are providing unprecedented insights into this disease and enabling personalized treatment approaches. Patient-derived organoids maintain the specific mutations and drug sensitivities of each patient's tumor, allowing testing multiple chemotherapy regimens and targeted therapies to identify effective treatments before exposing the patient to ineffective toxic options. This is particularly critical for recurrent ovarian cancer where patients have already failed first-line therapy and need guidance selecting among multiple potential second-line treatments. Large biobanks of ovarian cancer organoids enable researchers to correlate specific genetic mutations with drug responses across hundreds of patients, revealing biomarkers that predict treatment success. Normal ovarian and fallopian tube organoids are also providing insights into how ovarian cancer initiates, potentially enabling early detection strategies or preventive interventions for high-risk women.
Ovarian organoids are 3D tissue models derived from ovarian tissue, modeling either normal ovarian epithelium or ovarian cancer. Healthy ovarian organoids contain epithelial cells resembling fallopian tube or ovarian surface epithelium. Ovarian cancer organoids from patient tumors maintain tumor characteristics including mutations in genes like TP53, BRCA1/2, and others, enabling personalized medicine and cancer research.
Yes, testing chemotherapy drugs on patient ovarian cancer organoids predicts clinical response. Platinum-based chemotherapy, PARP inhibitors for BRCA-mutant cancers, and other treatments are tested to identify effective options before treating the patient. Some studies show 80-90% concordance between organoid responses and patient outcomes, making organoids valuable for treatment selection, especially for recurrent ovarian cancer.
High-grade serous ovarian carcinoma (HGSOC) is the most common and deadly ovarian cancer subtype, accounting for 70% of ovarian cancer deaths. Nearly all HGSOC tumors have TP53 mutations and many have BRCA1/2 or homologous recombination deficiency. HGSOC organoids are extensively studied, with biobanks containing hundreds of patient lines enabling large-scale research into this devastating disease.
Ovarian cancer initially responds to platinum-based chemotherapy but often develops resistance. Organoids from recurrent tumors reveal resistance mechanisms including increased drug efflux, enhanced DNA repair, altered metabolism, and cancer stem cell enrichment. Testing drug combinations on resistant organoids identifies strategies to overcome resistance, like combining platinum with PARP inhibitors or immune checkpoint blockers.
Healthy ovarian and fallopian tube organoids study normal tissue physiology, ovulation processes, hormone responses, and early cancer development. Since many ovarian cancers actually originate in fallopian tubes, modeling normal fallopian tube epithelium and its transformation helps understand cancer initiation and identify early detection strategies or prevention approaches.
PARP inhibitors like olaparib block DNA repair enzymes, causing synthetic lethality in BRCA-mutant cancer cells that already have impaired DNA repair. Ovarian cancer organoids with BRCA1/2 mutations show high sensitivity to PARP inhibitors in drug testing, while BRCA-wildtype organoids are often resistant. Testing predicts which patients benefit from PARP inhibitors.
Yes, ovarian cancer often causes ascites - fluid accumulation in the abdomen containing floating tumor cells. These cells can be collected non-invasively and grown into organoids, providing an accessible tumor sample source without surgery. Ascites-derived organoids enable repeated sampling to track treatment response, resistance development, and tumor evolution over time.
Ovarian cancer exists in a complex microenvironment with stromal fibroblasts, immune cells, and ascites fluid. Standard organoid cultures lack these components. Advanced models add cancer-associated fibroblasts, immune cells, or culture organoids in patient-derived ascites fluid to better recapitulate the tumor microenvironment and how it affects drug responses and cancer progression.
Large ovarian cancer organoid biobanks enable correlating genetic mutations with drug sensitivities across hundreds of patients, identifying biomarkers predicting treatment response, discovering new therapeutic targets, testing combination therapies, and studying tumor heterogeneity. These resources accelerate research impossible with limited patient samples.
Organoids model major ovarian cancer subtypes: high-grade serous (most common, TP53-mutant), low-grade serous (KRAS/BRAF-mutant), clear cell (treatment-resistant), endometrioid, and mucinous carcinomas. Each subtype has distinct biology, drug sensitivities, and genetic profiles maintained in organoids, enabling subtype-specific research and treatment development.